---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-115161"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-10-13T10:03:00+00:00"
generated_at: "2026-10-13T10:05:31.791729+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma doses first patient in U.S. Phase 1 trial of ARR-002 for ovarian and endometrial cancer

## Summary
- ArriVent (Nasdaq: AVBP) dosed the first patient in the U.S. Phase 1 trial (NCT07755436) of ARR-002, a MUC16/NaPi2b dual-target tetravalent ADC.
- ARR-002 is a potential first-in-class MUC16/NaPi2b dual-target ADC for ovarian and endometrial cancer; both targets are highly over-expressed in these cancers.
- Stuart Lutzker, President of R&D, said ARR-002 is ArriVent's second ADC to enter the clinic, broadening the pipeline beyond lung and gastrointestinal cancers.
- In August 2026, ArriVent licensed ARR-002 from Shanghai Allist Pharmaceuticals for Greater China, including mainland China, Hong Kong, Macau, and Taiwan, retaining all other rights.

## SEC filing metadata
- accession: 0001104659-26-115161
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-10-13T10:03:00+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/0001104659-26-115161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-115161
- JSON: https://secwatch.observer/filing/0001104659-26-115161.json
- Plain text: https://secwatch.observer/filing/0001104659-26-115161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.